# MCTA (Charming Medical Limited) - SEC EDGAR Financial Statements

> Charming Medical Limited reported $4.81M in revenue and a net loss of $23K for the fiscal year ended March 31, 2026 (down 22.7% year over year), with a 99.3% gross margin and a -0.6% operating margin.

- Canonical: https://convexityos.com/fundamentals/MCTA
- Markdown: https://convexityos.com/fundamentals/MCTA.md
- SEC CIK: 0002035992
- Reporting currency: USD
- Latest filing period: March 31, 2026
- Last synced: Nov 20, 2026, 05:37 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002035992&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | $4.81M | -22.7% YoY |
| Operating Income | FY 2026 | -$29K | -0.6% margin |
| Net Income | FY 2026 | -$23K | -0.5% net margin |
| Diluted EPS | FY 2026 | $0.00 | Split-adjusted |
| Free Cash Flow | FY 2026 | -$1.56M | -32.4% FCF margin |
| Cash & ST Investments | Mar 31, 2026 | $4.70M | Total debt: $908K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 |
| --- | --- | --- | --- |
| **Revenue** | $4.81M | $6.22M | $6.02M |
| Cost of Revenue | $35K | $16K | $11K |
| **Gross Profit** | $4.77M | $6.21M | $6.00M |
| Total Operating Expenses | $4.84M | $4.83M | $5.01M |
| **Operating Income** | -$29K | $1.39M | $1.01M |
| **EBITDA** | $187K | $1.65M | $1.40M |
| Interest Income | $73K | $64K | $20K |
| Interest Expense | $16K | $21K | $26K |
| Income Before Tax | $133K | $1.44M | $1.00M |
| Income Tax Expense | $156K | $236K | $182K |
| **Net Income** | -$23K | $1.20M | $778K |
| Basic EPS | $0.00 | $0.08 | $0.05 |
| **Diluted EPS** | $0.00 | $0.08 | $0.05 |
| Basic Shares Outstanding | 16.2M | 15.3M | 15.3M |
| Diluted Shares Outstanding | 16.2M | 15.3M | 15.3M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2026 | FY 2025 |
| --- | --- | --- |
| Cash & Cash Equivalents | $4.70M | $817K |
| **Cash & Short-Term Investments** | $4.70M | $817K |
| Accounts Receivable, Net | $201K | $396K |
| Inventory | $26K | $27K |
| **Total Current Assets** | $8.17M | $3.37M |
| Property, Plant & Equipment, Net | $607K | $500K |
| **Total Non-Current Assets** | $1.69M | $1.99M |
| **Total Assets** | $9.87M | $5.36M |
| Accounts Payable | $17K | $3.5K |
| Short-Term Debt | $186K | $314K |
| Deferred Revenue (Current) | $3.05M | $3.46M |
| Other Current Liabilities | $9.4K | $215K |
| **Total Current Liabilities** | $4.33M | $4.95M |
| **Total Non-Current Liabilities** | $356K | $358K |
| **Total Liabilities** | $4.69M | $5.31M |
| **Total Debt (incl. Leases)** | $908K | $1.16M |
| Retained Earnings | $97K | $119K |
| Accumulated Other Comp. Income | -$15K | -$3.6K |
| **Total Stockholders' Equity** | $5.18M | $49K |
| Total Equity | $5.18M | $49K |

### Balance Sheet (Quarterly)

| Line Item | Mar 2026 | Mar 2025 |
| --- | --- | --- |
| Cash & Cash Equivalents | $4.70M | $817K |
| **Cash & Short-Term Investments** | $4.70M | $817K |
| Accounts Receivable, Net | $201K | $396K |
| Inventory | $26K | $27K |
| **Total Current Assets** | $8.17M | $3.37M |
| Property, Plant & Equipment, Net | $607K | $500K |
| **Total Non-Current Assets** | $1.69M | $1.99M |
| **Total Assets** | $9.87M | $5.36M |
| Accounts Payable | $17K | $3.5K |
| Short-Term Debt | $186K | $314K |
| Deferred Revenue (Current) | $3.05M | $3.46M |
| Other Current Liabilities | $9.4K | $215K |
| **Total Current Liabilities** | $4.33M | $4.95M |
| **Total Non-Current Liabilities** | $356K | $358K |
| **Total Liabilities** | $4.69M | $5.31M |
| **Total Debt (incl. Leases)** | $908K | $1.16M |
| Retained Earnings | $97K | $119K |
| Accumulated Other Comp. Income | -$15K | -$3.6K |
| **Total Stockholders' Equity** | $5.18M | $49K |
| Total Equity | $5.18M | $49K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 |
| --- | --- | --- | --- |
| Net Income | -$23K | $1.20M | $822K |
| Depreciation & Amortization | $216K | $263K | $392K |
| Change in Receivables | $194K | -$44K | -$165K |
| Change in Inventory | $1.2K | $1.4K | $38K |
| **Operating Cash Flow** | -$1.22M | $426K | $295K |
| Capital Expenditure | -$340K | -$288K | -$211K |
| **Free Cash Flow** | -$1.56M | $138K | $85K |
| Purchases of Investments | -$11K | -$501K | -- |
| **Investing Cash Flow** | -$179K | -$2.23M | -$211K |
| **Financing Cash Flow** | $5.29M | $521K | $100K |
| **Net Change in Cash** | $3.90M | -$1.28M | $185K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 |
| --- | --- | --- | --- |
| **Gross Margin** | 99.3% | 99.8% | 99.8% |
| **Operating Margin** | -0.6% | 22.3% | 16.8% |
| **Net Profit Margin** | -0.5% | 19.3% | 12.9% |
| Return on Equity (ROE) | -0.4% | 2435.0% | -- |
| Return on Assets (ROA) | -0.2% | 22.4% | -- |
| Current Ratio | 1.89x | 0.68x | -- |
| Quick Ratio | 1.88x | 0.68x | -- |
| Debt to Equity | 0.18x | 23.57x | -- |
| **Revenue Growth (YoY)** | -22.7% | +3.4% | -- |
| Gross Profit Growth (YoY) | -23.1% | +3.4% | -- |
| Operating Income Growth (YoY) | -102.1% | +37.7% | -- |
| **Net Income Growth (YoY)** | -101.9% | +54.2% | -- |
| EPS Growth (YoY) | -100.0% | +60.0% | -- |
| Operating Cash Flow Growth (YoY) | -385.5% | +44.2% | -- |
| Free Cash Flow Growth (YoY) | -1224.2% | +63.1% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
